Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3600
+0.0080 (2.27%)
Nov 26, 2025, 4:00 PM EST - Market closed
Vaxart Employees
Vaxart had 105 employees as of December 31, 2024. The number of employees decreased by 4 or -3.67% compared to the previous year.
Employees
105
Change (1Y)
-4
Growth (1Y)
-3.67%
Revenue / Employee
$1,411,467
Profits / Employee
-$482,886
Market Cap
86.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 105 | -4 | -3.67% |
| Dec 31, 2023 | 109 | -55 | -33.54% |
| Dec 31, 2022 | 164 | 54 | 49.09% |
| Dec 31, 2021 | 110 | 82 | 292.86% |
| Dec 31, 2020 | 28 | 14 | 100.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VXRT News
- 8 days ago - Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript - Seeking Alpha
- 13 days ago - Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Vaxart to Host Upcoming Conference Calls - GlobeNewsWire
- 22 days ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 22 days ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 7 weeks ago - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewsWire
- 2 months ago - Vaxart Appoints W. Mark Watson as Lead Independent Director - GlobeNewsWire
- 2 months ago - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire